Literature DB >> 12933918

Intrathecal inflammation precedes development of Alzheimer's disease.

E Tarkowski1, N Andreasen, A Tarkowski, K Blennow.   

Abstract

OBJECTIVES: To analyse the cerebrospinal fluid (CSF) values of the proinflammatory cytokines, interleukin 1beta (IL1beta), tumour necrosis factor alpha (TNFalpha), GM-CSF, of the anti-inflammatory cytokine TGFbeta, of tau protein, a marker for neurodegeneration, and of beta amyloid (Abeta), a protein involved in the formation of senile plaques, in prospectively followed up patients with mild cognitive impairment (MCI).
METHODS: Analyses of CSF levels of TNFalpha, IL1beta, GM-CSF, TGFbeta, betaa, and tau protein were performed using ELISA in 56 patients with MCI who were followed up prospectively and in 25 age matched, healthy controls.
RESULTS: Patients with MCI displayed significantly higher levels of TNFalpha and tau protein and significantly lower levels of TGFbeta and Abeta compared with the healthy controls. After nine months of follow up, 25 patients still displayed MCI while the remaining 31 patients had progressed to Alzheimer's disease (AD). Only MCI patients who progressed to AD at follow up, showed significantly higher CSF levels of TNFalpha than controls. In addition, reduced CSF-Abeta42 levels were only found in MCI patients that progressed to AD, further supporting the notion that disturbed metabolism of Abeta is an early finding in AD.
CONCLUSIONS: These results demonstrate increased production of the proinflammatory cytokine, TNFalpha and decreased production of the anti-inflammatory cytokine TGFbeta in patients with MCI at risk to develop AD, suggesting a propensity towards inflammation in this patient group and indicating that CNS inflammation is a early hallmark in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12933918      PMCID: PMC1738668          DOI: 10.1136/jnnp.74.9.1200

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia.

Authors:  Elisabeth Tarkowski; Razao Issa; Magnus Sjögren; Anders Wallin; Kaj Blennow; Andrej Tarkowski; Pat Kumar
Journal:  Neurobiol Aging       Date:  2002 Mar-Apr       Impact factor: 4.673

3.  Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia.

Authors:  E Tarkowski; A Wallin; B Regland; K Blennow; A Tarkowski
Journal:  Acta Neurol Scand       Date:  2001-03       Impact factor: 3.209

4.  Intracerebral administration of interleukin-1beta and induction of inflammation, apoptosis, and vasogenic edema.

Authors:  S Holmin; T Mathiesen
Journal:  J Neurosurg       Date:  2000-01       Impact factor: 5.115

5.  TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD.

Authors:  E Tarkowski; A M Liljeroth; A Nilsson; A Ricksten; P Davidsson; L Minthon; K Blennow
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

Review 6.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

7.  Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

Authors:  N Andreasen; L Minthon; E Vanmechelen; H Vanderstichele; P Davidsson; B Winblad; K Blennow
Journal:  Neurosci Lett       Date:  1999-09-24       Impact factor: 3.046

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.

Authors:  P L McGeer; S Itagaki; H Tago; E G McGeer
Journal:  Neurosci Lett       Date:  1987-08-18       Impact factor: 3.046

10.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

View more
  159 in total

1.  Amelioration of age associated neuroinflammation on long term bacosides treatment.

Authors:  Manisha Rastogi; Rudra P Ojha; B Parimala Devi; Aabha Aggarwal; Aruna Agrawal; G P Dubey
Journal:  Neurochem Res       Date:  2011-12-25       Impact factor: 3.996

2.  Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease.

Authors:  Qiying Sun; Harald Hampel; Kaj Blennow; Simone Lista; Allan Levey; Beisha Tang; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Editorial: cytokine inhibition for treatment of Alzheimer's disease.

Authors:  Paul B Rosenberg
Journal:  MedGenMed       Date:  2006-04-26

4.  Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism.

Authors:  Edward Tobinick
Journal:  Medscape J Med       Date:  2008-06-10

5.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  ZO-1 expression is suppressed by GM-CSF via miR-96/ERG in brain microvascular endothelial cells.

Authors:  Hu Zhang; Shuhong Zhang; Jilin Zhang; Dongxin Liu; Jiayi Wei; Wengang Fang; Weidong Zhao; Yuhua Chen; Deshu Shang
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-21       Impact factor: 6.200

7.  RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Authors:  Fang Fang; Lih-Fen Lue; Shiqiang Yan; Hongwei Xu; John S Luddy; Doris Chen; Douglas G Walker; David M Stern; Shifang Yan; Ann Marie Schmidt; John X Chen; Shirley ShiDu Yan
Journal:  FASEB J       Date:  2009-11-11       Impact factor: 5.191

8.  Systemic Tumor Necrosis Factor-Alpha Trajectories Relate to Brain Health in Typically Aging Older Adults.

Authors:  Cutter A Lindbergh; Kaitlin B Casaletto; Adam M Staffaroni; Fanny Elahi; Samantha M Walters; Michelle You; John Neuhaus; Will Rivera Contreras; Paul Wang; Anna Karydas; Jesse Brown; Amy Wolf; Howie Rosen; Yann Cobigo; Joel H Kramer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-07-13       Impact factor: 6.053

9.  Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.

Authors:  Nofar Torika; Keren Asraf; Ella Roasso; Abraham Danon; Sigal Fleisher-Berkovich
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

10.  RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.

Authors:  Dimitry Ofengeim; Sonia Mazzitelli; Yasushi Ito; Judy Park DeWitt; Lauren Mifflin; Chengyu Zou; Sudeshna Das; Xian Adiconis; Hongbo Chen; Hong Zhu; Michelle A Kelliher; Joshua Z Levin; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.